Utility of platelet function analyzer as a screening tool for the diagnosis of Von Willebrand disease in adolescents with menorrhagia

Authors

  • Swati Naik MD,

    1. Section of Hematology and Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
    Search for more papers by this author
  • Jun Teruya MD, DSc,

    1. Section of Hematology and Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
    2. Department of Pathology and Immunology and Medicine, Baylor College of Medicine, Houston, Texas
    Search for more papers by this author
  • Jennifer E. Dietrich MD, MSc,

    1. Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas
    Search for more papers by this author
  • Purvi Jariwala MHA, MT (ASCP),

    1. Section of Hematology and Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
    2. Department of Pathology and Immunology and Medicine, Baylor College of Medicine, Houston, Texas
    Search for more papers by this author
  • Esther Soundar MD, MPH,

    1. Department of Pathology and Immunology and Medicine, Baylor College of Medicine, Houston, Texas
    Search for more papers by this author
  • Lakshmi Venkateswaran MD

    Corresponding author
    1. Section of Hematology and Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
    • Texas Children's Hospital/Baylor College of Medicine, 6701 Fannin Street CC 1510.00, Houston, TX.
    Search for more papers by this author

  • Conflict of interest: Nothing to declare.

Abstract

Background

Von Willebrand disease (VWD), and in particular, VWD type 1 and low VW factor (defined as Von Willebrand Ristocetin cofactor activity (RCoF) <30 and <50 IU/dl, respectively with normal multimers) are frequently detected in adolescents with menorrhagia and both groups benefit from similar management. Platelet function analyzer (PFA-100®) is often used as a screening test to detect VWD. We analyzed the utility of PFA-100® as a screening tool in the detection of VWD type 1 and low VW factor (VWF) in an exclusive adolescent population with menorrhagia.

Methods

The study population consisted of adolescents with menorrhagia who had simultaneously drawn blood samples for VWD and PFA-100®. Abnormal PFA-100® was defined as values >183 seconds for collagen/epinephrine and/or >126 seconds for collagen/ADP.

Results

Of a total of 235 patients tested, 23 patients had RCoF <50 IU/dl and normal multimer patterns. Statistical analysis of the utility of PFA-100® in detecting RCoF <50 IU/dl with normal multimers yielded sensitivity, specificity, positive predictive, and negative predictive values of 52%, 89%, 34%, and 95%, respectively.

Conclusions

Based on our results, PFA-100® was not sufficiently sensitive to detect RCoF values <50 IU/dl with normal multimer patterns in teen-aged women with menorrhagia. We conclude that in the setting of adolescent menorrhagia, PFA-100® does not have utility as an initial screening test for the diagnosis of VWD and in particular, low VWF and that clinicians need to be aware of this limitation of PFA-100® while evaluating adolescents with menorrhagia. Pediatr Blood Cancer 2013; 60: 1184–1187. © 2013 Wiley Periodicals, Inc.

Ancillary